You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

877 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    dexamethasone
May 2022
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Jun 2019
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Sep 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma
May 2024

Pages